TekniPlex Healthcare Signs Definitive Purchase Agreement To Acquire Seisa Medical

Our Bureau

TekniPlex Healthcare, which utilizes advanced materials science expertise to help deliver better patient outcomes, has signed a definitive agreement to acquire Seisa Medical in a deal that significantly extends TekniPlex Healthcare’s medical technology solutions platform. This acquisition specifically enhances the company’s materials science and process technologies for minimally invasive and […]

U.S.-trained DOs gain global recognition

Our Bureau

The International Association of Medical Regulatory Authorities (IAMRA) approved a resolution today to support the recognition of U.S.-trained DOs as fully licensed physicians equivalent to MDs in 47 IAMRA member countries during its 15th biennial Members General Assembly in Bali, Indonesia. The resolution was jointly submitted by the Federation of State Medical Boards (FSMB) and the […]

Peach State Health Plan, Pyx Health Announce Partnership to Combat Social Isolation, Loneliness and Depression in Georgia Youth

Our Bureau

Today, Peach State Health Plan, a care management organization that serves the needs of Georgians through a range of health insurance solutions and wholly owned subsidiary of Centene Corporation (NYSE: CNC), announced a new partnership with Pyx Health, a health care technology company, in a new initiative to combat social isolation, loneliness and depression in […]

Bio-Botanica® announces Puresterol® (pueraria mirifica) based serums found to reduce wrinkles in clinical trials

Our Bureau

Bio-Botanica, Inc., ® the one American company that has manufactured botanical extracts under one family for more than 50 years, has revealed the results of clinical trials indicating its proprietary botanical extract ingredient, Puresterol® (Pueraria mirifica), showed positive effects on the reduction of wrinkles when used in a face serum. Pueraria mirifica grows […]

PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data

Our Bureau

PharmAbcine, Inc. (“PharmAbcine” or the “Company”) (KOSDAQ: 208340), a clinical-stage public company focused on developing novel antibody therapies for patients, today announced that the Safety Review Committee (SRC) has approved advancing to dose level 2 of the PMC-403 Phase 1 clinical study in neovascular age-related macular degeneration patients following completion of dose […]

BioCare In-House Expertise to Guide Customers on Effectively Preparing for the Drug Supply Chain Security Act (DSCSA)

Our Bureau

BioCare today released a white paper on the Drug Supply Chain Security Act (DSCSA) and how companies can prepare for compliance with the U.S. Food and Drug Administration’s (FDA) requirements to ensure all medications are genuine, uncontaminated, and uncompromised.  The DSCSA final phase includes the enforcement of exchanging serialized data at […]

Terray Therapeutics Announces Investment from NVIDIA to Enable Generative AI Design for Drug Discovery

Our Bureau

Terray Therapeutics, a biotechnology company integrating scale experimentation and generative AI to improve the speed, cost, and success rate of small molecule drug discovery and development, today announced an equity investment by NVentures, NVIDIA’s venture capital arm. Additional financing included a strong syndicate of new and existing institutional investors, including […]

March Biosciences and Cancer Focus Fund Announce $4.8 Million Investment to Support a Phase 2 Clinical Trial of Novel CAR-T Therapy for T-Cell Lymphoma

Our Bureau

March Biosciences (March Bio), a clinical stage biotechnology company committed to combating challenging cancers unresponsive to existing immunotherapies, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) to provide funding and clinical expertise to advance promising cancer therapies, today […]

Subscribe Now